Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Durability of Protection against COVID-19 Breakthrough Infections and Severe Disease by Vaccines in the United States

Amanda Zheutlin, Miles Ott, Ran Sun, Natalia Zemlianskaia, Meagan Rubel, Jennifer Hayden, Breno Neri, Tripthi Kamath, Najat Khan, Sebastian Schneeweiss, Khaled Sarsour
doi: https://doi.org/10.1101/2022.01.05.22268648
Amanda Zheutlin
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miles Ott
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran Sun
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Zemlianskaia
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meagan Rubel
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Hayden
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Breno Neri
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tripthi Kamath
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Najat Khan
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Schneeweiss
2Department of Science, Aetion Inc., New York, NY
3Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khaled Sarsour
1Data Science, Research & Development, Janssen Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ksarsour@its.jnj.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives Determine durability of protection by the three currently available COVID-19 vaccines in the United States (US) following primary vaccination against breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions.

Methods Using claims and laboratory data covering 168 million lives, we conducted a matched case-control study with fully vaccinated individuals between January 1 and September 7, 2021. Odds ratios (OR) for developing outcomes in months two through six following full vaccination were estimated relative to the first month after full vaccination for each vaccine separately.

Results Evidence of waning protection against infections started in month 2 from vaccination for both BNT162b2 (OR [95% CI] in month 6+, 2.93 [2.72, 3.15]) and mRNA-1273 (OR [95% CI] in month 6+, 2.76 [2.51, 3.04]), and in month 4 for Ad26.COV2.S (OR [95% CI] in month 5+, 1.31 [1.18, 1.47]). Evidence of waning protection against hospitalization started in month 2 for BNT162b2 (OR [95% CI], 3.97 [3.26, 4.83] in month 6+) and in month 3 for mRNA-1273 (OR 95% CI, 1.66 [1.26, 2.19] in month 6+). There was no evidence of waning protection against hospitalization for Ad26.COV2.S (OR [95% CI], 1.25 [0.86, 1.80] in month 5+). No waning of protection was observed at any time for ICU admissions for all three vaccines.

Conclusions Following primary vaccination, all three vaccines showed strong and durable protection against ICU admissions. Ad26.COV2.S showed a more durable level of protection against breakthrough infections and hospitalizations in line with published evidence of its durable antibody and cellular immune response, although its Vaccine Effectiveness (VE) at baseline after a single-dose is lower than that for the two-dose mRNA vaccines. Additional studies are needed to understand durability following homologous or heterologous boosters.

Competing Interest Statement

All authors with the exception of Dr. Schneeweiss are employees of Janssen R&D the manufacturer of Ad26.COV2.S.

Dr. Schneeweiss is participating in investigator-initiated grants to the Brigham and Womens Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc. which has multiple research collaborations with Janssen R&D.

Funding Statement

This work was funded by Janssen Research & Development.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The collection and analysis of these data did not qualify as human subjects research under the Common Rule and were not subject to institutional review board assessment. The New England institutional review board approved this exemption (no.1-9757-1). Upon reasonable request, researchers may get access to the data and analytics infrastructure for prespecified collaborative analyses.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding This work was funded by Janssen Research & Development.

  • Conflicts of Interest Dr. Zheutlin, Dr. Ott, Dr. Sun, Dr. Zemlianskaia, Dr. Rubel, Ms. Hayden, Dr. Neri, Dr. Kamath, Dr. Khan and Dr. Sarsour are employees of Janssen R&D, the manufacturer of Ad26.COV2.S.

    Dr. Schneeweiss is participating in investigator-initiated grants to the Brigham and Women’s Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc. of which he owns equity. He did not receive consultancy fees from Janssen before, during, or after this study was conducted. His interests were declared, reviewed, and approved by the Brigham and Women’s Hospital in accordance with their institutional compliance policies.

Data Availability

Upon reasonable request, researchers may get access to the data and analytics infrastructure for prespecified collaborative analyses.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 06, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Durability of Protection against COVID-19 Breakthrough Infections and Severe Disease by Vaccines in the United States
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Durability of Protection against COVID-19 Breakthrough Infections and Severe Disease by Vaccines in the United States
Amanda Zheutlin, Miles Ott, Ran Sun, Natalia Zemlianskaia, Meagan Rubel, Jennifer Hayden, Breno Neri, Tripthi Kamath, Najat Khan, Sebastian Schneeweiss, Khaled Sarsour
medRxiv 2022.01.05.22268648; doi: https://doi.org/10.1101/2022.01.05.22268648
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Durability of Protection against COVID-19 Breakthrough Infections and Severe Disease by Vaccines in the United States
Amanda Zheutlin, Miles Ott, Ran Sun, Natalia Zemlianskaia, Meagan Rubel, Jennifer Hayden, Breno Neri, Tripthi Kamath, Najat Khan, Sebastian Schneeweiss, Khaled Sarsour
medRxiv 2022.01.05.22268648; doi: https://doi.org/10.1101/2022.01.05.22268648

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (413)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (393)
  • Epidemiology (8550)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1744)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1237)
  • Health Policy (619)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10281)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1670)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (926)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (112)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (247)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1764)
  • Public and Global Health (3832)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (319)
  • Respiratory Medicine (520)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (157)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (74)